Business
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax® approved by the U.S. FDA for the treatment of locally
About this update from Novocure Limited
[{"type":"text","content":"\nFull year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million\n\n\nOptune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch underway\n\n\n BAAR, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).\n\n\n“In 2025, a record number of patients received treatment with Novocure’s Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advancing the treatment of cancer with our technology,” said Frank Leonard, CEO, Novocure. “This momentum continues in 2026 with the U.S. FDA approval of Optune Pax for pancreatic cancer, an achievement we are incredibly proud of given the exceptional challenge of developing treatment for this disease. We are well-positioned to continue to drive our patient-forward mission while prioritizing our goal of achieving profitability.”\n\n\nFinancial updates for the year and fourth quarter ended December 31, 2025:\n\n\n\nTotal net revenues for the year were $655.4 million, an increase of 8% year-over-year.\n\n\n\nTotal net revenues for the fourth quarter were $174.4 million, an increase of 8% year-over-year, primarily driven by an increase in active patients on therapy.\n\n\nThe U.S., Germany, France and Japan contributed $101.6 million, $21.3 million, $20.3 million and $10.2 million in quarterly net revenues, respectively, with our other active markets contributing $16.3 million.\n\n\n\nRevenue in Greater China from Novocure’s partnership with Zai Lab totaled $4.6 million.\n\n\n\nRecognized revenue from Optune Lua® in the fourth quarter was $3.5 million, including $2.4 million from non-small cell lung cancer (NSCLC) and $1.1 million from malignant pleural mesothelioma (MPM).\n\n\n\n\n\n\n\nGross margin for the quarter was 76%, compared to 79% in the same period in 2024. The reduction was primarily driven by the continued roll out of our Head Flexible Electrode (HFE) array for use with Optune Gio®, costs associated with treating NSCLC patients prior to establishing reimbursement and increased tariffs.\n\n\...